drugset

Drugs / EP102

Follow last change Apr 2026 re-read 3 minutes ago

EP102

Investigated by: Epics Therapeutics

Trials 1

today NCT07163325 · Ph 1

20262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT07163325	Jul 2025 → Nov 2027 expected	—	Epics Therapeutics	Recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 4

Date	Issuer	Release
2026-04-09	Epics Therapeutics	Results EPICS to Present Preclinical Data on METTL3 Inhibitor EP102 at American Association for Cancer Research Annual Meeting 2026 epicstherapeutics.com ↗ EP102 demonstrated significant, dose-dependent tumor growth inhibition in a PDAC xenograft model².
2025-10-22	Epics Therapeutics	Results EPICS To Present Preclinical Data on METTL3 Inhibitor EP102 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Boston, October 22-26, 2025) epicstherapeutics.com ↗
2023-12-08	Epics Therapeutics	Results EP102, a METTL3 inhibitor that demonstrates strong stand-alone in vivo efficacy and synergistic activity with venetoclax for the treatment of acute myeloid leukemia will be presenting at the ASH 2023 conference epicstherapeutics.com ↗ Single agent dose dependent in vivo efficacy was shown in several animal models using human AML tumor cells.
2023-04-11	Epics Therapeutics	Results EPICS Therapeutics presents compelling in vivo efficacy in oncology with its proprietary METTL3 inhibitor at AACR 2023 epicstherapeutics.com ↗ This METTL3 inhibitor significantly prolonged survival in an orthotopic (intratibial) models of CDX and patient-derived AML tumors with selective targeting of blood cancer cells (human CD45+) relative to general hematopoiesis

All press releases naming this drug 6 releases

Date	Issuer	Release
2026-04-14	Epics Therapeutics	EPICS Publishes Discovery and Optimization of its METTL3 Inhibitor EP102 in Journal of Medicinal Chemistry epicstherapeutics.com ↗
2026-04-09	Epics Therapeutics	EPICS to Present Preclinical Data on METTL3 Inhibitor EP102 at American Association for Cancer Research Annual Meeting 2026 epicstherapeutics.com ↗
2025-10-22	Epics Therapeutics	EPICS To Present Preclinical Data on METTL3 Inhibitor EP102 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Boston, October 22-26, 2025) epicstherapeutics.com ↗
2025-09-22	Epics Therapeutics	EPICS Therapeutics Announces First Cohort Dosed with EP102 in First-In-Patient Oncology Trial and Securement of Additional Financing epicstherapeutics.com ↗
2023-12-08	Epics Therapeutics	EP102, a METTL3 inhibitor that demonstrates strong stand-alone in vivo efficacy and synergistic activity with venetoclax for the treatment of acute myeloid leukemia will be presenting at the ASH 2023 conference epicstherapeutics.com ↗
2023-04-11	Epics Therapeutics	EPICS Therapeutics presents compelling in vivo efficacy in oncology with its proprietary METTL3 inhibitor at AACR 2023 epicstherapeutics.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	EP102	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07163325 ↗
Route	Oral	“EP102 will be administered orally” NCT07163325 ↗